Accelerate Diagnostics
AXDX
AXDX was delisted on the 14th of May, 2025.
46 hedge funds and large institutions have $8.33M invested in Accelerate Diagnostics in 2024 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 11 reducing their positions, and 3 closing their positions.
3,300% more call options, than puts
Call options by funds: $34K | Put options by funds: $1K
167% more first-time investments, than exits
New positions opened: 8 | Existing positions closed: 3
67% more capital invested
Capital invested by funds: $4.98M → $8.33M (+$3.35M)
12% more funds holding
Funds holding: 41 → 46 (+5)
64% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$730K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$234K |
| 3 |
Renaissance Technologies
New York
|
+$60.9K |
| 4 |
YIH
Y-Intercept (HK)
Hong Kong
|
+$29.4K |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$18.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Griffin Asset Management
New York
|
-$200K |
| 2 |
Group One Trading
Chicago,
Illinois
|
-$15.7K |
| 3 |
VF
Virtu Financial
New York
|
-$12K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$11.5K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$7.95K |
AXDX Hedge Fund Activity: Q3 2024 in Review
46 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Accelerate Diagnostics (AXDX) for Q3 2024, worth a combined $8.33M — up 67% from $4.98M a quarter earlier.
Buyers outnumbered sellers: 8 funds opened new AXDX positions and 3 closed out — a net gain of 5 holders — while 4 added to existing stakes and 11 trimmed.
The largest buyer was Armistice Capital, adding an estimated $730K. The largest seller was Griffin Asset Management, cutting an estimated $200K.
- 46 institutional investors held Accelerate Diagnostics (AXDX) as of Q3 2024, up from 41 in Q2 2024.
- Funds reported $8.33M of Accelerate Diagnostics stock for Q3 2024, up 67% quarter-over-quarter.
- 8 funds opened new Accelerate Diagnostics positions in Q3 2024 and 3 closed out, a net change of +5 holders.
- The largest Accelerate Diagnostics buyer in Q3 2024 was Armistice Capital, an estimated $730K added.
- The largest Accelerate Diagnostics seller in Q3 2024 was Griffin Asset Management, an estimated $200K sold.
Based on aggregated 13F filings for Q3 2024.